AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by Amundi

Amundi lowered its position in AtriCure, Inc. (NASDAQ:ATRC) by 10.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 270,455 shares of the medical device company’s stock after selling 31,393 shares during the period. Amundi owned about 0.55% of AtriCure worth $9,104,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Heck Capital Advisors LLC purchased a new position in AtriCure in the fourth quarter valued at about $60,000. Venturi Wealth Management LLC increased its holdings in AtriCure by 1,337.6% in the fourth quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company’s stock valued at $69,000 after buying an additional 2,100 shares in the last quarter. KBC Group NV increased its holdings in AtriCure by 65.3% in the fourth quarter. KBC Group NV now owns 2,360 shares of the medical device company’s stock valued at $72,000 after buying an additional 932 shares in the last quarter. R Squared Ltd purchased a new position in AtriCure in the fourth quarter valued at about $89,000. Finally, M&T Bank Corp purchased a new position in AtriCure in the fourth quarter valued at about $208,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ATRC. JMP Securities reaffirmed a “market outperform” rating and issued a $60.00 target price on shares of AtriCure in a report on Monday, February 10th. Oppenheimer increased their target price on shares of AtriCure from $36.00 to $45.00 and gave the company an “outperform” rating in a report on Thursday, February 13th. JPMorgan Chase & Co. increased their target price on shares of AtriCure from $40.00 to $51.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Needham & Company LLC reissued a “buy” rating and set a $51.00 price objective on shares of AtriCure in a research note on Thursday, February 13th. Finally, Piper Sandler raised their price objective on shares of AtriCure from $40.00 to $50.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $51.56.

Insiders Place Their Bets

In other AtriCure news, Director Karen Prange sold 6,100 shares of AtriCure stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total value of $232,532.00. Following the completion of the sale, the director now directly owns 17,828 shares of the company’s stock, valued at approximately $679,603.36. The trade was a 25.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.20% of the stock is owned by corporate insiders.

AtriCure Stock Up 1.7 %

ATRC stock opened at $33.31 on Friday. The stock has a market capitalization of $1.63 billion, a P/E ratio of -35.06 and a beta of 1.53. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.62 and a current ratio of 3.65. AtriCure, Inc. has a one year low of $18.94 and a one year high of $43.11. The company has a 50 day moving average price of $38.10 and a two-hundred day moving average price of $33.37.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.